Organization
Bologna, Italy
5 abstracts
Abstract
Histopathological response (HR) after neoadjuvant chemotherapy (ChT) for high-risk soft tissue sarcomas (STS): A planned analysis of the ISG-STS-1001 trial.Org: Department of Experimental Oncology, Milano, Italy, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Vall d'Hebron University Hospital, Bergonié Institute,
Abstract
Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).Org: Erasmus MC Cancer Center, Rotterdam, Netherlands Cancer Institute, Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands, Fondazione IRCCS Istituto Neurologico Carlo Besta,
Abstract
Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment.Org: Medical College of Wisconsin, Milwaukee, WI, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland, IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli” and Dipartimento di Medicina Specialistica,
Abstract
Early changes of PSMA PET signal after initiation of androgen receptor signaling inhibitors in mCRPC: An international multicenter retrospective study.Org: Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, UCLA Department of Medicine, Division of Nuclear Medicine,
Abstract
AUTOANTIBODIES PROFILE OF RHEUMATOID ARTHRITIS (RA) DURING INFLIXIMAB (INFL) TREATMENTOrg: Medicina Interna Bianchi, Policlinico S. Orsola, University of Bologna, Bologna, Italy,